Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

201 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The effect of the availability of inhaled insulin on glycaemic control in patients with Type 2 diabetes failing on oral therapy: the evaluation of Exubera as a therapeutic option on insulin initiation and improvement in glycaemic control in clinical practice (EXPERIENCE) trial.
Del Prato S, Blonde L, Martinez L, Göke B, Woo V, Millward A, Gomis R, Canovatchel B, Strack T, Lawrence D, Freemantle N; EXPERIENCE Trial Team. Del Prato S, et al. Among authors: blonde l. Diabet Med. 2008 Jun;25(6):662-70. doi: 10.1111/j.1464-5491.2008.02438.x. Epub 2008 Apr 23. Diabet Med. 2008. PMID: 18435781 Clinical Trial.
Impact of disease duration and β-cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on glucagon-like peptide-1 receptor agonist therapy: Exploratory analyses from the LixiLan-G trial.
Del Prato S, Frias JP, Blonde L, Aroda VR, Shehadeh N, Saremi A, Dex T, Niemoeller E, Souhami E, Liu M, Rosenstock J. Del Prato S, et al. Among authors: blonde l. Diabetes Obes Metab. 2020 Sep;22(9):1567-1576. doi: 10.1111/dom.14068. Epub 2020 May 28. Diabetes Obes Metab. 2020. PMID: 32323437 Free PMC article. Clinical Trial.
Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial.
Blonde L, Rosenstock J, Del Prato S, Henry R, Shehadeh N, Frias J, Niemoeller E, Souhami E, Ji C, Aroda VR. Blonde L, et al. Diabetes Care. 2019 Nov;42(11):2108-2116. doi: 10.2337/dc19-1357. Epub 2019 Sep 17. Diabetes Care. 2019. PMID: 31530665 Clinical Trial.
Switching to iGlarLixi versus continuation of a daily or weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) in insufficiently controlled type 2 diabetes: A LixiLan-G trial subgroup analysis by HbA1c and GLP-1 RA use at screening.
Rosenstock J, Blonde L, Aroda VR, Frias J, Souhami E, Ji C, Niemoeller E, Del Prato S. Rosenstock J, et al. Among authors: blonde l. Diabetes Obes Metab. 2021 Jun;23(6):1331-1341. doi: 10.1111/dom.14345. Epub 2021 May 4. Diabetes Obes Metab. 2021. PMID: 33565209 Free PMC article.
Real-world trials to answer real-world questions.
Freemantle N, Blonde L, Bolinder B, Gerber RA, Hobbs FD, Martinez L, Ross S. Freemantle N, et al. Among authors: blonde l. Pharmacoeconomics. 2005;23(8):747-54. doi: 10.2165/00019053-200523080-00001. Pharmacoeconomics. 2005. PMID: 16097837
201 results